6
Oct
2022

Nobel for Bertozzi, Red Tree Eyes West Coast, & Doubling Down on Singapore

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Jazz Scoops Up Epilepsy Drug, Boulevard Aims for Immune Reset, & AbCellera Matures
Takeda Wins First-in-Class Orexin OK, Lilly’s Obesity Money Gusher, & Three New IPOs
J&J Buys In Vivo CAR-T, Sarepta’s New Boss, & Three IPOs in the Queue
Dimension Hauls In $800M, Arrowhead Nails Triglycerides, Tempus Buys Personalis